SapVax
SapVax develops a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications.
SapVax develops a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications.